Skip to main content
NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%
OT

Ocular Therapeutix, Inc. (OCUL)

NASDAQ • Healthcare

$11.47
+$0.1 (+0.9%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$11.24
Day Range$11.02 - $11.48
Avg. Volume (3M)2.8M
Market Cap$2.5B
52 Week Range
$6.23$16.44
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$13.4M100%
Gross Profitminus cost of goods$11.4M85%

Fundamentals & Financials

Revenue (TTM)
$52M
Net Income (TTM)
-$301.4M
EPS (TTM)
-$1.42
ROA (TTM)
-44.9%
Current Ratio
13.11
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+12.1%Q1 2026-$0.29
-28.1%Q2 2026-$0.41
+11.5%Q3 2026-$0.35
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +11.5%

Ocular Therapeutix topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 3, 2026, with EPS of -$0.35 topping the -$0.40 estimate by $0.05 and revenue of $13.5 million topping the $13.2 million estimate (+2%). Revenue was essentially flat year over year, rising 0.1% to about $13.5 million (up from about $13.5 million a year ago), reflecting results from its ophthalmic portfolio built on its bioresorbable hydrogel technology, including products such as DEXTENZA and ReSure Sealant. Profitability remained shaped by a high gross margin, with gross profit of roughly $11.5 million and gross margin at about 85%, while operating income was -$82.1 million. Net income was -$78.8 million, down 16.1% year over year from roughly -$67.8 million a year ago. For the next period, consensus calls for EPS of -$0.36 on revenue of $14.3 million.

View full earnings history

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. develops ophthalmic treatments in the healthcare biotechnology field. Listed on the NASDAQ as OCUL, the company sells eye-care products built around a proprietary bioresorbable hydrogel technology and recorded $51.8 million in revenue in FY2025, with marketed and pipeline programs both focused on diseases of the eye.

Name
Ocular Therapeutix, Inc.
CEO
Pravin U. Dugel
Website
www.ocutx.com
Industry
Healthcare
Year Founded
2006
Employees
325

Today's Snapshot

AI-generated

OCUL closed 0.9% higher at 11.47.

Trading Volume

Above 10d avg 1.9M

2.8M

vs S&P 500 Today

Outperforming Market

+1.36%

Updated: September 10, 2026 at 12:09 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
OCUL exhibits several constructive technical features: momentum readings like a mid-60s RSI and a strong CCI are supportive while the MACD is modestly positive, indicating upward momentum. Price sits above short- and medium-term moving averages and also above the 200-day averages, reinforcing a bullish bias, while ADX near the mid-20s suggests trend strength is present but not extreme. Volatility is moderate based on ATR and Bollinger positioning, and on-balance volume is flagged as a buy. Technical takeaway: the chart displays a strong-buy configuration supported by momentum, moving averages and supportive OBV.
All signals
  • EMA (5 indicators)$9.78 - $10.91
    Buy
  • RSI (14)65.47
    Neutral
  • Stochastic %K (14, 3, 3)66.21
    Neutral
  • MACD Level (12, 26)0.40
    Buy

Peers & Related Assets

IBRXImmunityBio, Inc.
$8.06-2.8%
LQDALiquidia Corporation
$69.12+2.1%
COGTCogent Biosciences, Inc.
$34.18-3.1%
EWTXEdgewise Therapeutics, Inc.
$43.39-1.0%
RCUSArcus Biosciences, Inc.
$28.49-2.0%
VRDNViridian Therapeutics, Inc.
$22.73-1.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.